Find a Cancer Provider

Are you a referring physician?
I am searching for a
Marcia Brose, MD, PhD

Marcia Brose, MD, PhD Physician

Associate Professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania
Associate Professor of Medicine

Dr. Brose is a Penn Medicine employed physician.

About Dr. Marcia Brose

Recognized by Best Doctors in America 2011-2012

Clinical Specialties


  • Medicine
    • Medical Oncology
  • Otorhinolaryngology

Programs & Centers:

  • Cancer
    • Center for Head and Neck Cancer
  • Ear, Nose and Throat - Head and Neck Surgery
    • Head and Neck Cancer Surgery
    • Thyroid

Clinical Expertise:

  • Thyroid Cancer

Description of Clinical Expertise

Treatment of Thyroid Cancer, PhaseI/II/III clinical trials, novel drug target discovery, and use of genetic testing in diagnosis, prognostication and prediction of resopnse to the treatment of cancer. Treatment of Rare Cancers of the Head and Neck.

Practice Locations and Appointments

  • Head and Neck Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Weill Medical College of Cornell University
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Academy of Otolaryngology-Head and Neck Surgery, National American Association of Cancer Research, National American College of Physicians, National American Society for Clinical Oncology, National American Thyroid Association, National AstraZeneca, International Bayer Healthcare Pharmaceuticals and Bayer Scherring Pharma, International Eisai Inc., International Exelixis, International International Thyroid Oncology Group, International ONYX Pharmaceuticals, Inc., National OXiGENE, National Pennsylvania Society of Oncology and Hematology, Local The Endocrine Society, National University of Pennsylvania - American Cancer Society Pilot Program IRG, Local

Hospital Affiliation

Dr. Brose is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Dr Brose is the director of the Thyroid Cancer Therapuetics Program and is a global leader in the development of the new field of thyroid cancer oncology. Her Phase II clinical trial of sorafenib in patients with advanced thyroid cancer lead to the successful completion of the first Phase III study, in this disease group (RAI refractory thyroid cancer). She was also one of the top accuers and lead site for the Phase III trial of cabozantinib for advance medullary thyroid cancer, which lead to FDA approval of this agent in November of 2012. Requested to speak and teach worldwide on her experience in the the use of novel agents to treat patients with all types of advanced thyroid cancer (Differentiate, Medullary, and Anaplastic), she is a global leader and educator to physicians and patients alike.

Dr. Brose also runs a lab in the field of translational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. Most of her research centers on translational projects directly related to samples obtained in the course of her clinical trial program. However, occasionally, science leads to leads in other tumor types. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincal tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis, and whole and targeted genome sequencing. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.

Selected Publications:

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.: Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 33 (7): 786-809,2015.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI.: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer N Engl J Med 372 (7): 621-630,2015.

Brose MS, Schlumberger M, Peña C, Kappeler C: Sorafenib for patients with differentiated thyroid cancer--authors' reply. Lancet 385 (9964): 228-229,2015.

Yarchoan M, LiVolsi VA, Brose MS: BRAF mutation and thyroid cancer recurrence. J Clin Oncol. 33 (1): 7-8,2015.

Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.: A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24 (10): 1508-1514,2014.

Cohen AB, Brose MS: Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials. J Clin Endocrinol Metab. 99 (6): 1995-7,2014.

Brose,M.S., Nutting,C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt,L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, YK, Sherman, SI, Smit, JWA, Chung, J., Kappeler, C., Pena, C., Molnar, I., Schlumberger, M.J., on behalf of the DECISION Investigators*: Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase III trial The Lancet 14 : 60421-9,2014.

Brose,M.S., Frenette,C.T., Keefe, S.M., Stein, S.M.: Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective Seminars in Oncology 41 (1): S1-S16,2014.

View all publications

Academic Contact Info

Stellar Chance Building 8M

422 Curie Blvd.

Philadelphia, PA 19104
Phone: (215) 746-6344
Fax: (215) 898-2136
Patient appointments: 800-789-PENN (7366)

Related Links